Search clinical trials for: Fluticasone Propionate Placebo

Total 54721 results

GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma

Asthma

China
GlaxoSmithKline

Completed

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
University of Chicago
Merck Sharp & Dohme LLC

Terminated

The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Rhinitis, Allergic, Perennial

United States
Almirall, S.A.

Completed

A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid

Asthma

Germany, United Kingdom
GlaxoSmithKline

Completed

Viapaed Study In Children And Adolescents With Asthma

Asthma

Germany
GlaxoSmithKline

Completed

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Asthma

Germany, Romania, Bulgaria, Chile, Russian Federation, South Africa, Estonia, Italy, Mexico, Greece, Hungary, Croatia, Brazil
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
GlaxoSmithKline

Completed

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Bronchial Asthma

Japan
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Japan, Poland, Romania, Russian Federation, Spain, Ukraine, Germany, Taiwan, Bulgaria, Hungary, France, Philippines, South Africa, Thailand, Israel, Korea, Republic of, Australia, Mexico, Slovakia, United... and more
Bristol-Myers Squibb

Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Hepatitis C Virus

France, Spain, United Kingdom, United States, Germany, Italy, Argentina, Ireland
MEDA Pharma GmbH & Co. KG

Completed

Dymista Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
Western Sky Medical Research
GlaxoSmithKline

Completed

Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis
Cipla Ltd.

Completed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Bronchial Asthma

United States
Creighton University
Roche Pharma AG

Completed

Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges* (Roche)

Allergy

United States
Meda Pharmaceuticals

Completed

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
GlaxoSmithKline

Completed

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Asthma

Germany, France
GlaxoSmithKline

Completed

Spacer Comparison In Adult Asthmatics

Asthma

New Zealand
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
University of Miami

Completed

Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment (smoker3)

Smoking

United States
Meda Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Seasonal Allergic Rhinitis

United States
Mundipharma Research Limited

Completed

Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma (FLT2503)

Asthma

Germany
GlaxoSmithKline

Terminated

Study In Asthma Control

Asthma

Canada
GlaxoSmithKline

Completed

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Bronchospasm | Activity/Exercise Induced Bronchospasm

United States
GlaxoSmithKline

Completed

Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)

Asthma

Korea, Republic of
Dey

Completed

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

Healthy

United States
GlaxoSmithKline

Completed

Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics

Asthma

Germany
Orion Corporation, Orion Pharma

Completed

Phase I Pharmacokinetic Study (SALBLOCK) (SALBLOCK)

Healthy Volunteer Study

Finland
West Penn Allegheny Health System

Completed

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Egalet Ltd

Completed

Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects

Healthy Subjects

United Kingdom
Mahidol University

Recruiting

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis | Child, Only

Thailand
Dana-Farber Cancer Institute
Roche-Genentech

Active, not recruiting

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Graft vs. Host Disease

United States
GlaxoSmithKline

Completed

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects

Asthma

Australia
Kindeva Drug Delivery

Completed

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Healthy

United Kingdom
GlaxoSmithKline

Completed

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Asthma

United States, Peru, Kenya, Puerto Rico
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Pulmonary Disease, Chronic Obstructive

Japan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

Asthma

China
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Exercise Performance

Denmark
Padagis LLC

Completed

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
SkyePharma AG

Completed

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients

Asthma

United Kingdom, Ireland
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Asthma

United Kingdom, Germany, Hungary, Poland, Romania
Radboud University Medical Center
GlaxoSmithKline; Zambon SpA; The Netherlands Asthma Foundation; Dutch Health Care...

Completed

COPD on Primary Care Treatment (COOPT)

Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

Netherlands
Mundipharma Research Limited

Completed

Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma

Asthma

Romania, Hungary, Czechia, France, Germany, Poland
GlaxoSmithKline

Completed

Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

Asthma
GlaxoSmithKline

Terminated

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States

3

Subscribe